Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
19:55:00 25/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 77.36 EUR | -0.46% |
|
+1.20% | +23.97% |
| Market Cap | 13.43B 15.3B 12.68B 11.56B 21.64B 1,467B 21.79B 152B 58.79B 749B 57.46B 56.22B 2,408B | P/E 2026 * |
25.8x | P/E 2027 * | 20.4x |
|---|---|---|---|---|---|
| Enterprise Value | 16.8B 19.14B 15.86B 14.46B 27.06B 1,834B 27.25B 190B 73.52B 937B 71.86B 70.31B 3,012B | EV / Sales 2026 * |
2.21x | EV / Sales 2027 * | 2.06x |
| Free-Float |
60.39% | Yield 2026 * |
1.04% | Yield 2027 * | 1.17% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ERF | Real-time | |
CBOE
| Real-time | ||
|
OTC Markets
| ERFSF | Delayed | |
|
Tradegate
| ESF0 | Real-time | |
|
Boerse Muenchen
| ESF0 | Real-time | |
|
Börse Stuttgart
| ESF0 | Delayed | |
|
Xetra
| ESF0 | Delayed | |
|
Deutsche Boerse AG
| ESF0 | Delayed | |
|
London S.E.
| 0MV5 | Delayed | |
|
CBOE
| 0MV5 | Real-time | |
|
Wiener Boerse
| ESF | End-of-day quote | |
|
Borsa Italiana
| 4ERF | End-of-day quote |
Last Transcript: Eurofins Scientific SE
| 1 day | -0.46% | ||
| 1 week | +1.20% | ||
| Current month | +6.64% | ||
| 1 month | +4.43% | ||
| 3 months | +13.30% | ||
| 6 months | +24.85% | ||
| Current year | +23.97% |
| 1 week | 75.8 |  | 79.22 |
| 1 month | 68.38 | | 79.22 |
| Current year | 56.84 | | 79.22 |
| 1 year | 54.86 | | 79.22 |
| 3 years | 39.47 | | 79.22 |
| 5 years | 39.47 | | 120.6 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 01/01/1987 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 01/01/2015 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 01/10/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 01/01/1987 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 01/01/2015 |
Valérie Hanote
BRD | Director/Board Member | 60 | 01/01/1990 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 27/04/26 | Buy | 700 | 0.0004% | |||
| 19/04/26 | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 19/04/26 | Exercice | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.46% | +1.20% | +26.78% | +41.32% | 15.3B | |
| -0.14% | +4.33% | +9.88% | +31.73% | 47.97B | |
| -1.69% | +1.48% | +53.02% | +33.59% | 44.5B | |
| +2.56% | +7.34% | +382.17% | +594.81% | 43.93B | |
| +0.24% | +2.85% | +9.78% | +89.54% | 41.03B | |
| -0.62% | -1.11% | +4.70% | +46.02% | 29.85B | |
| -0.28% | +1.07% | +26.83% | +152.91% | 17.27B | |
| -2.21% | -4.70% | - | - | 14.82B | |
| +3.37% | +9.21% | +9.93% | - | 15.34B | |
| -0.54% | +5.32% | +101.17% | +48.22% | 13.98B | |
| Average | +0.02% | +2.57% | +69.36% | +129.77% | 28.4B | |
| Weighted average by Cap. | +0.08% | +2.95% | +83.98% | +150.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.58B 8.64B 7.16B 6.53B 12.22B 828B 12.31B 85.71B 33.2B 423B 32.45B 31.75B 1,360B | 8B 9.11B 7.55B 6.88B 12.89B 874B 12.98B 90.39B 35.01B 446B 34.22B 33.48B 1,434B |
| Net income | 531M 605M 501M 457M 855M 57.99B 862M 6B 2.32B 29.63B 2.27B 2.22B 95.21B | 660M 752M 623M 568M 1.06B 72.06B 1.07B 7.46B 2.89B 36.81B 2.82B 2.76B 118B |
| Net Debt | 3.37B 3.84B 3.18B 2.9B 5.42B 368B 5.46B 38.04B 14.73B 188B 14.4B 14.09B 604B | 3.03B 3.46B 2.87B 2.61B 4.89B 331B 4.92B 34.29B 13.28B 169B 12.98B 12.7B 544B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/09/26 | €77.36 | -0.46% | 274,276 |
| 24/09/26 | €77.72 | +2.05% | 240,165 |
| 23/09/26 | €76.16 | -3.55% | 263,405 |
| 22/09/26 | €78.96 | +1.15% | 340,282 |
| 21/09/26 | €78.06 | +2.12% | 308,980 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
